For PatientsPrescribing InformationProvider Login
hero-drop-mobile
THE FIRST AND ONLY
FDA-approved eye drop for adults with low-lying eyelids
Meet Upneeq

Upneeq lifts tired-looking eyelids fast

Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, is the first and only FDA-approved prescription eye drop for your adult patients with low-lying eyelids (also known as acquired blepharoptosis or ptosis). It provides a non-surgical eyelid lift, quickly lifting eyelids and opening the eyes wider.

Just one drop per eye, once daily, is clinically proven to give your patients visible results — lifted and open eyelids in as fast as 5 minutes that can last up to 8 hours.

No more tired-looking eyes, Upneeq can provide your patients with more awake-looking eyes. Introduce your patients to the eye drop that lifts.

BEFORE
AFTER
After
Before

Actual patient. Individual results may vary. Average upper eyelid lift with Upneeq in clinical studies was 1 mm.

Treat patients with low-lying eyelids

Get Your Patients Started Today

Benefits of Upneeq

Visible results

When it comes to eyelids, a little lift goes a long way. Upneeq provides a non-surgical eyelid lift for your patients that is clinically proven to lift and open upper eyelids.

Fast-acting, long-lasting

Just one drop in each eye can temporarily lift your patient’s upper eyelids in as little as 5 minutes, and last up to 8 hours.

Easy to incorporate

Upneeq comes in single-use vials, and is FDA-approved for once daily use. For your patients, this makes it easy to fit Upneeq into their everyday routines.

Get Your Patients Started

In clinical trials of Upneeq

84%

of patients have had some form of improvement in eyelid lift.

88%

of patients have had some form of improvement in their upper field of vision.

Learn More About Our Story

Delivers rapid, visible lift to the upper eyelid with once-daily use

Mean change from baseline in upper eyelid elevation (MRD-1) after dosing Upneeq (data from pooled analysis of 2 clinical trials) * 1
Mean Change Chart
Upneeq (n=203)
Vehicle (n=101)
Error bars represent standard deviation of the mean change from baseline.
  1. Upneeq increased upper eyelid elevation significantly more than vehicle in clinical trials, as measured by MRD-1 (on Day 1 and Day 14 of treatment). 2
    1. Achieved average eyelid lift of 1mm. 3

  2. In one clinical trial, onset of elevation as shown by improvement in MRD-1 began in some patients 5 minutes after Upneeq was administered (the earliest time point measured). 3
    1. RVL-1201-202, Upneeq (n=109) vs. vehicle (n=55).
MRD-1=Marginal Reflex Distance 1 (distance from the central pupillary light reflex to the central margin of the upper lid).

AS SEEN IN

get-started-section-background-mobile

Give your patients eye-opening results with Upneeq

Get Your Patients Started
Location

Become an Upneeq provider and help patients find your practice

Sign Up as a Provider
References
1. Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020.
2. Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. RVL Pharmaceuticals, Inc. 2024.
3. Data on file, RVL Pharmaceuticals, Inc.

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.


IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.


DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.


IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.


DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.

About UpneeqBefore and AfterWhat is Acquired PtosisResourcesContact Us
Prescribing Information
Privacy PolicyTerms of Use
FacebookTikTokInstagram

Distributed by: RVL Pharmaceuticals, Inc. Bridgewater, NJ 08807.©2025 RVL Pharmaceuticals, Inc. All rights reserved. PM-US-UPN-1741 03/25

Upneeq® is a registered trademark of RVL Pharmaceuticals, Inc.